Regorafenib in Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically confirmed colorectal adenocarcinoma * Measurable metastatic disease. * Age +/\> 70 * Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options * Life expectancy \>/= 12 weeks * Able to understand and willing to sign written informed consent. * Laboratory requirements: * Total bili ≤ 1.5 x upper limit or normal * Alanine aminotransferase \& Asparate aminotransferase ≤ 2.5 x upper limit or normal * Serum creatinine ≤ 1.5 x upper limit or normal * International normalized ratio/prothrombin time ≤ 1.5 x upper limit or normal * Platelet count ≥ 100,000, hemoglobin ≥ 9 g/dL * Absolute neutrophil count ≥ 1,500. Blood transfusion to meet the inclusion criteria not be allowed. * Glomerular filtration rate ≥ 60 ml/min * Subjects of childbearing potential must agree to use adequate contraception beginning at the signing informed consent form until at least 3 months after the last dose of study drug. * Must be able to swallow and retain oral medications Exclusion Criteria: * Currently receiving other systemic therapy for metastatic colorectal cancer * Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. * Uncontrolled hypertension despite optimal medical management * Active or clinically significant cardiac disease. * Evidence or history of bleeding diathesis or coagulopathy * Any hemorrhage or bleeding event ≥ grade 3 within 4 weeks. * Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within 6 months of informed consent * History of other active malignancy within past 2 years. * Patients with phaeochromocytoma * Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection. * Ongoing infection \> grade 2 * Symptomatic metastatic brain or meningeal tumors * Presence of non-healing wound, non-healing ulcer, or bone fracture * Renal failure requiring hemo- or peritoneal dialysis * Dehydration ≥ grade 1 * Patients with seizure disorder requiring medication * Persistent proteinuria ≥ grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consent * Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea * History of organ allograft including corneal transplant * Known or suspected allergy or hypersensitivity to the study drug * Any malabsorption condition * Any condition which makes the subject unsuitable for trial participation * Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study.